CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 32 enrolled
Drug / intervention
DBPR108 +1 moredrug
Likely dose
DBPR108 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01650324
NCT01650324Phase 1Completed
CompareCT.gov

A Double-blind, Randomized, Placebo-controlled, Dose-ranging, Single-dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DBPR108 in Healthy Male Subjects

National Health Research Institutes, Taiwan·interventional·Posted Jul 26, 2012·Updated Aug 28, 2014

In Brief

A Phase 1 clinical trial evaluating DBPR108 and matching placebo for Diabetes Mellitus, Type 2. Completed, enrolled 32 participants across 1 site.

Detailed Summary

The study is being performed to assess the safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) properties of single oral doses of DBPR108 in healthy male subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesTaiwan
Collaborators--

Timeline

Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJul 26, 2012
Enrollment StartJul 1, 2012
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 13.9 years ago

Interventions

DBPR108drug

DBPR108 capsules in four doses beginning at 25 mg and rising to 600 mg.

matching placebodrug

Matching placebo capsules in four doses beginning at 25 mg and rising to 600 mg.